Navigation Links
Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
Date:7/5/2011

AMSTERDAM, July 6, 2011 /PRNewswire/ --


 

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced the appointment of Dr. Carlos R. Camozzi as Chief Medical Officer. Dr. Camozzi brings to AMT more than 25 years of pharmaceutical industry experience, most recently within the orphan drug field. This includes overseeing product approvals at the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).

"We are very fortunate to have attracted Carlos to AMT. He has joined the company at a pivotal point as we continue to pursue the approval our lead gene therapy Glybera with the EMA," stated Jörn Aldag, CEO of AMT. "His expertise in product development and related interaction with global regulatory bodies in the orphan drug field will prove invaluable, not only with Glybera, but also as we advance development of our gene therapy pipeline."

Dr. Camozzi will join AMT on July 18 from Orphan Europe, where he held the position of Medical Director for over 5 years. During his tenure, he oversaw the approval of Carbaglu, a product for hyperammonemia in NAGS deficiency and Organic Acidemias, with the EMA and FDA, EMEA marketing authorisation renewals for two products, three orphan drug designations and development of pediatric investigation plans. He was also responsible for the clinical development in the pediatric field of orphan drugs in therapeutic areas of metabolic disorders, immunology, dermatology, cardiology and CNS.

Prior to Orphan Europe, Dr. Camozzi was a strategic development manager in the Molecular Pathology department of Basel University Hospital, Basel, Switzerland. In this role, he interacted with both pharmaceutical customers and regulatory authorities. From 2001-2005, he was managing director of MCP-medeor consulting pharma, where he helped design preclinical and clinical development programs for pharmaceutical and healthcare products. Dr. Camozzi started his career in South America holding roles at Lederle/American Cyanamid and F Hoffmann La-Roche.

Dr. Camozzi earned his MD and PhD from the School of Medicine, National University of Buenos Aires (Argentina), and holds degrees in Paediatrics, Neonatology, Clinical Pharmacology and Neuropsychiatry.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. The company's lead product Glybera®, a gene therapy for lipoprotein lipase deficiency (LPLD), is currently under review by the European Medicines Agency (EMA). If approved, Glybera will be the first gene therapy product to be marketed in Europe. AMT also has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy,""expects,"" plans,""anticipates,""believes, ""will,""continues," "estimates,""intends,"" projects,""goals,""targets " and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law. 



'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
2. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
3. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
7. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
8. Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications
9. Biochemist and Geneticist Ronald W. Davis Receives $500,000 Gruber Genetics Prize for Pioneering Work in the Development of Biotechnologies that Have Significantly Advanced the Fields of Molecular Genetics and Genomics
10. NIH grant ratchets up ASU research in molecular motors
11. SAIC-Frederick and Biomatrica Collaborate to Improve Molecular Analysis in Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology:
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):